Vancouver, British Columbia (PRWEB) May 14, 2013
Ondine Biomedical Inc. announces that its CEO, Carolyn Cross, will be a Plenary Session Speaker at the World Congress of the of the International Photodynamic Association (IPA) on May 28th through May 31st, 2013. Carolyn Cross will be representing the field of work in Photodisinfection (also known as antimicrobial Photodynamic Therapy or aPDT). Ondine Biomedical is the global leader in the design and development of Photodisinfection based therapies, and is involved with all aspects of technology, product and clinical development through to commercialization of photodisinfection products. Photodisinfection based applications under development at Ondine include products for the dental, hospital acquired infection prevention (VAP, SSI, UTI, Blood Catheter, GI) and chronic sinusitis markets. Ms. Cross stated her speech will provide an “excellent opportunity to talk about the advances Ondine has made in Photodisinfection in a variety of applications and the larger implications those advances represent for Photodynamic technology.”
The IPA World Congress is a biannual conference highlighting the advances in scientific and clinical research around the world. This year's Congress is being held May 28th to May 31st, 2013 at the Ritz-Carlton Hotel, Seoul, Korea. All of the leaders in the field of PDT and their work will be represented during this event. Clinicians, scientists, researchers, hospital administrators, students are welcome to participate at this year's conference. Registration details are available here: IPA Registration
About the International Photodynamic Association
The IPA was founded in 1986 and its membership consists of the most prominent international clinicians and scientists involved in performing and researching photodynamic therapy (PDT) and photodiagnosis (PD). The purpose of the IPA is to promote the study of diagnosis and treatment using light and photosensitisers, to disseminate such information to the members of the IPA, the medical community and to the general public. The IPA organises an International Congress every two years to highlight leading research activities in the clinical and basic research aspects of PDT
About Carolyn Cross:
Carolyn Cross is the founder and CEO of Ondine Biomedical Inc., formed in 1999, and has over 18 years of direct experience working with early stage companies and has 25 years of experience with public market securities. Previously, Carolyn was responsible for managing pension, pooled, mutual and private client funds as a Vice President with Royal Bank Investment Management Inc., the fund management arm of the Royal Bank of Canada. Carolyn is currently a member of the Women’s Presidents Organization, the International Women’s Forum, the Toronto Society of Financial Analysts, the Courthill and Cherie Blair Foundations, and the Association for Professionals in Infection Control and Epidemiology. Carolyn Cross is the Founder of OrGenX Biopharma Corporation, a WEConnect certified company.
Read the full story at http://www.prweb.com/releases/papdt/WorldCongress/prweb10728611.htm.
Copyright©2012 Vocus, Inc.
All rights reserved